Oragenics Announces Termination of At-The-Market Offering Program
23 Januar 2024 - 11:34PM
Business Wire
Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the
“Company”) today announced it has terminated its previously
announced “at-the-market” (“ATM”) equity offering program.
The Company has initiated the 5-day termination process of the
ATM offering, with the termination to take effect on January 30,
2024. The Company will make no sales under the ATM offering during
this period.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy securities, nor will there be any
sale of the securities in any province, state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
the registration or qualification under the securities laws of any
such
About Oragenics
Oragenics, Inc. is a development-stage company focused on nasal
delivery of pharmaceutical medications including in neurology and
fighting infectious diseases including coronaviruses and
multidrug-resistant organisms. It’s ONP-002 product candidate is a
fully synthetic neurosteroid being developed to treat Mild
Traumatic Brain Injury (mTBI). Its NT-CoV2-1 product candidate is
an intranasal vaccine candidate to prevent COVID-19 and variants of
the SARS-CoV-2 virus. The NT-CoV2-1 program leverages coronavirus
spike protein research licensed from the National Institutes of
Health (NIH) and the National Research Council of Canada (NRC) with
a focus on reducing viral transmission and offering a more
patient-friendly intranasal administration. For more information,
please visit www.oragenics.com.
About ONP-002
ONP-002 is a fully synthetic neurosteroid being developed to
treat mTBI. In preclinical studies, the drug demonstrated
equivalent or better neuroprotective effects compared with related
neurosteroids. Animal models of concussion showed the drug reduces
the behavioral pathology associated with brain injury symptoms such
as memory impairment, anxiety and motor/sensory performance.
Additionally, ONP-002 is lipophilic and can cross the blood-brain
barrier to rapidly eliminate swelling, oxidative stress and
inflammation while restoring proper blood flow.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240123889060/en/
Oragenics, Inc. Janet Huffman, Chief Financial Officer
813-286-7900 jhuffman@oragenics.com
LHA Investor Relations Tirth T. Patel 212-201-6614
tpatel@lhai.com
Oragenics (AMEX:OGEN)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Oragenics (AMEX:OGEN)
Historical Stock Chart
Von Jun 2023 bis Jun 2024